INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2024-01-01 ms6000001594127539 来自上海

审稿速度:1.0
偏重的研究方向：基础医学;综述;肿瘤治疗
经验分享：20231023 初次投稿
20231025 reject 综述需要在题目里带有review，修改重投
20231026 重新投稿，两三天之后under review
20231120 结束审稿，给了一个月大修
20231219 修回
20231222 又重新送回审稿人手里 under review
20231231 accept
全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。

25 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-08-25 Aab12w3 来自北京

这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。

31 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-08-27 125a246am56暂无昵称来自安徽省

偏重的研究方向：蛋白;生物材料
经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？

25 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-09-20 lovebanana 来自江苏省

偏重的研究方向：肿瘤;药物化学
经验分享：有没有是cancer letter让转投过来的？机会大不大？

40 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-08-15 125a246am56暂无昵称来自安徽省

偏重的研究方向：多糖
经验分享：二审35天还没消息，大家时间是多少啊

31 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2024-04-29 ms6000000883616809 来自安徽省

想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2020-03-29 ms7269483029162029

嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-09-14 ms3000000496472263 来自四川省

偏重的研究方向：生物大分子
经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2024-02-08 ms1000001139242253 来自海南省

没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178606, encodeId=dc1521e860647, content=审稿速度:1.0 偏重的研究方向：基础医学;综述;肿瘤治疗 经验分享：20231023 初次投稿 20231025 reject 综述需要在题目里带有review，修改重投 20231026 重新投稿，两三天之后under review 20231120 结束审稿，给了一个月大修 20231219 修回 20231222 又重新送回审稿人手里 under review 20231231 accept 全程有三个审稿人，一共提了20+个意见，审稿速度算飞速的了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6aa8254344, createdName=ms6000001594127539, createdTime=Mon Jan 01 16:19:48 CST 2024, time=2024-01-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2154515, encodeId=37f22154515ce, content=这个刊物最近是怎么了呀，感觉处理速度好慢，7.31早上就with editor，到现在状态一点没变，NC也不至于with editor一个月吧，听说这个杂志催编辑压根没用，已经开始焦虑了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26b85400525, createdName=Aab12w3, createdTime=Fri Aug 25 11:20:16 CST 2023, time=2023-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154856, encodeId=0d682154856c5, content=偏重的研究方向：蛋白;生物材料 经验分享：请问大修是一个审稿人意见，已经返修回去，还会邀请审稿人出新的意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Sun Aug 27 23:15:58 CST 2023, time=2023-08-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2158669, encodeId=ca45215866945, content=偏重的研究方向：肿瘤;药物化学 经验分享：有没有是cancer letter让转投过来的？机会大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Sep 20 10:18:43 CST 2023, time=2023-09-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2152878, encodeId=4dfc21528e8d4, content=偏重的研究方向：多糖 经验分享：二审35天还没消息，大家时间是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dbfa2580368, createdName=125a246am56暂无昵称, createdTime=Tue Aug 15 14:59:31 CST 2023, time=2023-08-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2201117, encodeId=601a220111e2c, content=想问下大佬们这个期刊除了投稿人其他作者能看到稿件状态吗，拒稿会发邮件吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b328275001, createdName=ms6000000883616809, createdTime=Mon Apr 29 19:17:11 CST 2024, time=2024-04-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=858882, encodeId=d4a9858882d1, content=嗯，很快，已经接收3篇了，友好的期刊和审稿人，当然提出的修改意见很中肯，希望该期刊志能尽快跨入一区，突破5分，还会支持的！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Sun Mar 29 11:19:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157657, encodeId=17f2215e657b5, content=偏重的研究方向：生物大分子 经验分享：我9.1号投的，当天with editor ，到现在都还没动静。有没有一样的呀？有点着急了，看这个期刊最近都超级慢 - -, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78e8753922, createdName=ms3000000496472263, createdTime=Thu Sep 14 12:47:03 CST 2023, time=2023-09-14, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2186444, encodeId=2307218644450, content=没审稿，直接DIP 写信催给决定，回复以下，没动静了，有经验的大神在吗怎么办 Your manuscript was transferred to our transfer team looking for a better suited journal. The transfer process may take a few days to complete. When you receive a letter of confirmation of transfer, you can accept or decline the transfer. Best regards,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e6a65458119, createdName=ms1000001139242253, createdTime=Thu Feb 08 05:53:18 CST 2024, time=2024-02-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2157119, encodeId=e113215e1190b, content=偏重的研究方向：分子生物学 经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6ntVHaKIrYflbNlrQKh1D8Sf0QGhuGiaUls32f7GwMpYBjWCRAuGp5aOB1yIN6zrJJognTELqVZFKAsy8WMLTqA/132, createdBy=aafc2336762, createdName=Markxiao, createdTime=Mon Sep 11 12:55:19 CST 2023, time=2023-09-11, status=1, ipAttribution=香港)]

2023-09-11 Markxiao 来自香港

偏重的研究方向：分子生物学
经验分享：投稿第三天直接decision in process 请问这是直接拒稿吗？有没有相同经历的人麻烦分享一下谢谢

36 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务